512 — Grand Pharmaceutical Balance Sheet
0.000.00%
Last trade - 00:00
- HK$13.90bn
- HK$14.96bn
- HK$10.53bn
- 59
- 89
- 49
- 78
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,131 | 2,357 | 2,866 | 2,483 | 2,474 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,555 | 1,716 | 2,149 | 2,207 | 3,121 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,816 | 5,319 | 6,779 | 6,887 | 7,016 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,264 | 3,410 | 3,802 | 3,942 | 3,986 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 13,813 | 16,984 | 21,057 | 22,371 | 22,515 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,590 | 4,303 | 5,566 | 6,455 | 5,731 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 5,438 | 5,745 | 7,664 | 8,231 | 7,358 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 8,375 | 11,240 | 13,393 | 14,140 | 15,158 |
Total Liabilities & Shareholders' Equity | 13,813 | 16,984 | 21,057 | 22,371 | 22,515 |
Total Common Shares Outstanding |